Mark Levis, MD, PhD from The Johns Hopkins University, Baltimore, MD discusses treatment of acute myeloid leukemia (AML) patients. Although there is still little understanding of the pathogenesis of AML, practitioners do know to target CD19 - a B-cell specific surface protein. Two targeted therapies are currently available in AML therapy, inotuzumab and blinatumomab. Inotuzumab is very indiscriminate while contrastingly blinatumomab, a bi-specific T-cell engager (BiTEs), is very specific. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.